Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Low-density lipoprotein Stories

2013-09-06 08:23:09

RALEIGH, N.C., Sept. 6, 2013 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the appointment of William Cromwell, M.D. as Chief Medical Officer. "We are delighted to welcome Dr. William Cromwell back to LipoScience," said Bob Greczyn, interim chief executive officer, LipoScience, Inc. "Dr. Cromwell's...

2013-09-04 12:32:25

MAPLE GROVE, Minn., Sept. 4, 2013 /PRNewswire/ -- September is National Cholesterol Education Month and leading cardiologist Dr. Carl Lavie, Medical Director of Cardiac Rehabilitation and Prevention at the John Ochsner Heart and Vascular Institute, New Orleans, LA, urges all Americans to know the basic facts about cholesterol management. A recent study from the Centers for Disease Control and Prevention reports that awareness about the importance of cholesterol management is on the...

2013-09-04 12:32:23

JUPITER study data published in Circulation, suggest HDL-P may be a better marker of residual risk than HDL cholesterol or apolipoprotein A-1 in patients on statin therapy RALEIGH, N.C., Sept. 4, 2013 /PRNewswire/ -- LipoScience, Inc., (NASDAQ: LPDX) a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the publication of data...

2013-09-04 08:14:56

In a randomized trial that included about 2,000 patients with or at high risk of cardiovascular disease (CVD), use of a fixed-dose combination medication for blood pressure, cholesterol, and platelet control compared to usual care resulted in significantly improved medication adherence after 15 months and small improvements in systolic blood pressure and low-density lipoprotein cholesterol, according to a study in the September 4 issue of JAMA. "The long-term use of cardiovascular disease...

2013-09-03 23:26:48

This September, save 10% on all heart health testing orders from Request A Test. This offer expires September 31, 2013. Brecksville, OH (PRWEB) September 03, 2013 This September Request A Test, a leading national provider of direct to consumer lab testing, is offering 10% off of all lab testing orders from the Heart Health category. Customers should use promo code HEART10 when placing their order to take advantage of this savings opportunity. Heart disease continues to be the leading...

2013-09-02 09:53:11

Dr Gitt said: "There are wide variations between European countries in the achievement of LDL-cholesterol (LDL-C) targets. However the effect of different reimbursement systems on meeting the targets was unknown." Between June 2008 and February 2009 DYSIS assessed the prevalence and types of persistent lipid abnormalities in patients receiving statins. Eligible patients were at high risk of a cardiovascular event, aged >45 years, and had been on chronic statin treatment for at least...

2013-09-02 09:48:05

Dr Nakano said: "Many randomized clinical trials, such as Treating to New Targets (TNT) and PROVE IT-TIMI, have shown that aggressive cholesterol lowering with statins improves clinical outcomes in patients with CAD and high LDL-C levels.1,2 But until now it was not known whether aggressive lipid lowering with statins would also benefit CAD patients with very low LDL-C levels." The current study used the Ibaraki Cardiovascular Assessment Study (ICAS), a registry of 2,238 patients from 12...

2013-09-01 04:20:27

Pooled Data from Four Phase 2 Studies Demonstrated Consistent Reductions in LDL Cholesterol of Up to 59 Percent THOUSAND OAKS, Calif., Aug. 31, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced treatment with AMG 145 resulted in significant reductions in low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, of up to 59 percent in an efficacy analysis of pooled data from four 12-week Phase 2 studies evaluating AMG 145 in patient populations with high...

2013-08-31 08:20:18

Statistically Significant Reductions of up to 75 percent in Triglycerides and up to 79 percent in ApoC-III CARLSBAD, Calif., Aug. 31, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced interim data from an ongoing Phase 2 study of ISIS-APOCIII(Rx) as a monotherapy in patients with very high to severely high triglycerides. These data were presented today by Dr. Daniel Gaudet at a PACE session occurring concurrently with the European Society of Cardiology in...

2013-08-28 09:25:45

Lifestyle change, medication both linked to cholesterol improvements Two treatments that slow the development of diabetes also may protect people from heart disease, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Researchers examined the effect that making intensive lifestyle changes or taking the medication metformin had on cholesterol and triglyceride levels. The study, part of the National...